Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7639694 | 0.73 | RIPK1 (0.59) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL31374627 | 0.72 | RIPK1 (0.58) | RIPK1DAORETKDRCCNE1 | |
| SCHEMBL1538594 | 0.70 | DAO (0.46) | RIPK1DAOCCNE1CDK2CCNB2 | |
| SCHEMBL3672721 | 0.69 | RIPK1 (0.54) | RIPK1DAOCCNE1CDK2CCNB2 | |
| SCHEMBL451378 | 0.69 | RIPK1 (0.50) | RIPK1DAOCCNE1CDK2CCNB2 | |
| SCHEMBL29460546 | 0.69 | RIPK1 (0.65) | RIPK1RETKDRCCNB2CDK1 | |
| SCHEMBL142585 | 0.68 | DAO (0.47) | RIPK1DAORETKDRCCNB2 | |
| SCHEMBL1574005 | 0.68 | DAO (0.65) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL2595303 | 0.66 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL575029 | 0.66 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | claimed |
| US-20180186792-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2018-07-05 | — | — | US | claimed |
| US-9902724-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-02-27 | — | — | US | claimed |
| EP-3153180-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M Innovative Properties Company (US) | 2017-04-12 | — | — | EP | claimed |
| US-20170037045-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2017-02-09 | — | — | US | claimed |
| US-9475804-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-10-25 | — | — | US | claimed |
| EP-2717919-B1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES CO (US) | 2016-08-03 | — | — | EP | claimed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | claimed |
| US-20140227317-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-08-14 | — | — | US | claimed |
| EP-2717919-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M Innovative Properties Company (US) | 2014-04-16 | — | — | EP | claimed |
| WO-2007079171-A2 | TREATMENT FOR HODGKIN'S LYMPHOMA | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| EP-1804583-A2 | ADJUVANT FOR DNA VACCINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1799256-A2 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST HIV | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006130399-A2 | THERAPEUTIC COMBINATIONS AND METHODS INCLUDING IRM COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006063152-A2 | IMMUNOSTIMULATORY COMBINATIONS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2006042254-A2 | ADJUVANT FOR DNA VACCINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2006026394-A2 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST HIV | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060045885-A1 | Method of eliciting an immune response against HIV | GOVERNMENT OF THE UNITED STRATS OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2006-03-02 | — | — | US | claimed |
| US-20050267145-A1 | Treatment for lung cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2005-12-01 | — | — | US | claimed |
| US-20050226878-A1 | Therapeutic combinations and methods including IRM compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227317-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | RIPK1 2461/4885DAO 421/4885RET 2971/4885 |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | RIPK1 1185/4885DAO 1773/4885RET 2232/4885 |
| US-20170037045-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | RIPK1 2441/4885DAO 475/4885RET 2590/4885 |
| US-20180186792-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | RIPK1 2441/4885DAO 475/4885RET 2590/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | RIPK1 1185/4885DAO 1773/4885RET 2232/4885 |
| US-20060045885-A1 | Method of eliciting an immune response against HIV | CD69, IRF3, CD4 | RIPK1 672/4885DAO 3173/4885RET 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.